论文部分内容阅读
目的观察华蟾素联合介入疗法治疗中晚期肝癌的疗效。方法随机将156例中晚期肝癌患者分为两组,治疗组采用TACE+华蟾素;对照组采用单纯TACE治疗方法,观察两组治疗效果及不良反应等指标。结果治疗组、对照组有效率分别为28.2%(22/78),23.1%(18/78),两组差异无显著性(P>0.05),治疗组生活质量提高率53.8%(42/78),对照组生活质量提高率28.2%(22/78),两组有显著差异(P<0.05),治疗组骨髓抑制情况:I度30例,Ⅱ度40例,Ⅲ+IV度8例(10.3%),对照组I度30例,Ⅱ度24例,Ⅲ+IV度24例(30.8%),两组Ⅲ+IV度骨髓抑制发生率有显著差异(P<0.05)。结论 TACE术后给予华蟾素治疗能提高有效率,显著提高中晚期肝癌患者的生活质量,降低Ⅲ+IV期肝癌患者骨髓抑制的发生率,值得临床推广应用。
Objective To observe the effect of cinobufacini combined with interventional therapy in the treatment of advanced liver cancer. Methods 156 patients with advanced hepatocellular carcinoma (HCC) were randomly divided into two groups. TACE + cinobufotalin was used in the treatment group. TACE alone was used in the control group. The therapeutic effects and adverse reactions of the two groups were observed. Results The effective rates of the treatment group and the control group were 28.2% (22/78) and 23.1% (18/78) respectively, with no significant difference between the two groups (P> 0.05). The improvement rate of the quality of life in the treatment group was 53.8% (42/78) ), And the improvement rate of quality of life in the control group was 28.2% (22/78). There was significant difference between the two groups (P <0.05). The bone marrow suppression of the treatment group was 30 cases of I degree, 40 cases of Ⅱ degree and 8 cases of Ⅲ + 10.3%). There were 30 cases with I degree in control group, 24 cases with Ⅱ degree and 24 cases (30.8%) with Ⅲ + IV degree. There was a significant difference in the incidence of bone marrow suppression between Ⅲ and Ⅳ degrees in both groups (P <0.05). Conclusions Cinobufacini can improve the effective rate after TACE, improve the quality of life of patients with advanced hepatocellular carcinoma, and reduce the incidence of myelosuppression in patients with stage Ⅲ + Ⅳ hepatocellular carcinoma, which is worthy of clinical application.